Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (4)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
Liposomal amphotericin B (AmBisome), adult IV infusion
Renal measure
Clinical renal category or population named in the cited section
Source revision
DailyMed SPL version 14, effective 2026-10-02; posted Oct 05, 2026
Retrieved
2026-11-07 (not the revision date)
Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
Renal guidance: Clinical pharmacology, special populations; laboratory tests
The label describes use in patients with pre-existing impairment, but the effect of renal impairment on drug disposition has not been studied. Check kidney function and electrolytes, including potassium and magnesium. Confirm the liposomal formulation before use.
Source revision: DailyMed SPL version 14, effective 2026-10-02; posted Oct 05, 2026 | Retrieved: 2026-11-07. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Amphotericin B liposomal (AmBisome) - selected U.S. labeling
Adults receiving intravenous liposomal amphotericin B, specifically AmBisome. Not interchangeable with deoxycholate, lipid-complex or other amphotericin formulations.
Adults receiving intravenous liposomal amphotericin B, specifically AmBisome. Not interchangeable with deoxycholate, lipid-complex or other amphotericin formulations.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
AmBisome - product and source limitations
Check kidney function and electrolytes, including potassium and magnesium. Confirm the liposomal formulation before use.
How to use this: Apply only to the stated formulation, indication and renal population.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
Amphotericin B liposomal (AmBisome) - selected U.S. labeling
Adults receiving intravenous liposomal amphotericin B, specifically AmBisome. Not interchangeable with deoxycholate, lipid-complex or other amphotericin formulations.
Method: Qualitative renal/PK evidence; no label CrCl-based reduction table.
Adults receiving intravenous liposomal amphotericin B, specifically AmBisome. Not interchangeable with deoxycholate, lipid-complex or other amphotericin formulations.
Method: No renal dose reduction; source-specific weight convention
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Adults receiving intravenous liposomal amphotericin B, specifically AmBisome. Not interchangeable with deoxycholate, lipid-complex or other amphotericin formulations.
RDM31-amphotericin-b-liposomal-scope · Source section: Editorial scope tied to selected U.S. labelRenal section finder
Separate U.S. product-label layer
FDA / DailyMed dosing and renal information
Official
Amphotericin B liposomal (AmBisome) - selected U.S. labeling
U.S. product labeling / DailyMed · Adults receiving intravenous liposomal amphotericin B, specifically AmBisome. Not interchangeable with deoxycholate, lipid-complex or other amphotericin formulations.
Renal method: Qualitative renal/PK evidence; no label CrCl-based reduction table. Source date: Label revision date not separately recorded; retrieval date is not the revision date. Retrieved: 2026-09-05
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Labeled basic dosing
Labeled adult initial doses: empirical therapy 3 mg/kg IV daily; systemic fungal infection 3-5 mg/kg daily; HIV-associated cryptococcal meningitis 6 mg/kg daily. Infuse initially over about 120 minutes; approximately 60 minutes may be used when tolerated.
RDM31-amphotericin-b-liposomal-label-dose · Source locator: Dosage and Administration
Renal information and dialysis
Renal-impairment pharmacokinetics have not been studied, although patients with pre-existing dysfunction received treatment. No numeric CrCl reduction is provided. Hemodialysis/peritoneal dialysis do not appear to materially increase elimination.
RDM31-amphotericin-b-liposomal-label-renal · Source locator: Clinical Pharmacology: Special Populations; Overdosage
Selected warnings and limits
Monitor renal function and electrolytes. This product cannot be substituted milligram-for-milligram for another amphotericin formulation. Use only its own preparation instructions.
RDM31-amphotericin-b-liposomal-label-limits · Source locator: Precautions: Laboratory Tests; Dosage and Administration
DailyMed / product prescribing information · Liposomal amphotericin B (AmBisome), adult IV infusion
Renal method: Clinical renal category or population named in the cited section Source date: DailyMed SPL version 14, effective 2026-10-02; posted Oct 05, 2026 Retrieved: 2026-11-07
Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
Renal guidance: Clinical pharmacology, special populations; laboratory tests
The label describes use in patients with pre-existing impairment, but the effect of renal impairment on drug disposition has not been studied. Check kidney function and electrolytes, including potassium and magnesium. Confirm the liposomal formulation before use.
GlobalRPh RX List / product-label mirror · Liposomal amphotericin B (AmBisome), adult IV infusion
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
University of California San Francisco (UCSF) · Adults receiving intravenous liposomal amphotericin B, specifically AmBisome. Not interchangeable with deoxycholate, lipid-complex or other amphotericin formulations.
Renal method: No renal dose reduction; source-specific weight convention Source date: Revision date not stated on the reviewed page. Retrieved: 2026-09-05
Separate professional-source protocol; not automatically equivalent to product labeling.
Source-specific renal protocol
UCSF uses 4 mg/kg IV every 24 hours with flucytosine for cryptococcal meningitis, 5 mg/kg daily for invasive fungal infection, and 3 mg/kg daily for heme/BMT mold prophylaxis. These schedules are also listed for IHD and continuous dialysis. Monitor creatinine/electrolytes. Use total body weight unless it exceeds 120% of ideal weight, when adjusted weight is used.
The cryptococcal 4 mg/kg combination regimen differs from the label's 6 mg/kg regimen; preserve the entire selected treatment plan. The source's optional saline hydration requires assessment of fluid tolerance; it is not an instruction to mix saline into AmBisome.
Additional summaries stored on this page: 2 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
